Maia Biotechnology, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
AMEX
Solas Capital Management, LLC and Frederick Tucker Golden report beneficial ownership of 4.9% of MAIA Biotechnology, Inc. common stock.
AMEX
Solas Capital Management, LLC and Frederick Tucker Golden have reported beneficial ownership of 7.1% of MAIA Biotechnology, Inc.'s common stock as of March 31, 2026.
AMEX
FGMK Business Holdings, LLC and FGMK, LLC have jointly disclosed a 9.99% beneficial ownership stake in MAIA Biotechnology, Inc., primarily through a combination of open market purchases, private placements, and warrant exercises.
AMEX
Sergei M. Gryaznov, an insider at MAIA BIOTECHNOLOGY, INC., has filed an amended Schedule 13G reporting a beneficial ownership of 4.08% of the company's common stock as of December 31, 2023.